Skip to main content
ATOS logo

ATOS

Atossa Therapeutics, Inc.
$2.49 +0.21 (+9.21%) At close · Jul 7
Market Cap
$21.10M
Shares
8,611,361

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$1758 -95.6%
FY2015 Revenue FY2011–FY2015
Net Income
-$34.77M -36.3%
FY2025 Net Income FY2010–FY2025
Gross Margin
-7431.91% -7531.9pp
FY2015 Gross Margin FY2011–FY2015
Operating Margin
-725746.19% -695423.2pp
FY2015 Operating Margin FY2011–FY2015
Diluted EPS
-$4.04 -32.9%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$29.76M -41.5%
FY2025 Operating Cash Flow FY2011–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$1758 $1758 $40.14K $632.56K $481.84K $1500
$132.41K $132.41K $0 $345.52K $35.75K $5164
-$130.65K -$130.65K $40.14K $137.09K $416.21K -$95.69K
-7431.91% 100% 21.67% 86.38% -6379.33%
$21.81M $21.19M $14.12M $17.33M $15.08M $9.21M $6.61M $6.65M $4.21M $2.33M $770.43K $2.36M $1.11M $1.11M $1.97M
$17.79M $15.96M $13.5M $14.04M $12.61M $11.31M $8M $10.62M $7.22M $4.86M $6.48M $8.85M $8.05M $8.56M $3.04M $3.17M
$27.6K $30.8K $30K $103.04K
$8000 $23K $47K $52.79K $44.2K $128.99K $303.48K $272.63K $480.31K $472.93K $130.55K $15.62K
$39.6M $37.14M $27.62M $31.38M $27.69M $20.52M $14.61M $17.27M $11.43M $7.65M $7.97M $12.63M $12.21M $10.92M $5.49M $3.33M
-$39.6M -$37.14M -$27.62M -$31.38M -$27.69M -$20.52M -$14.61M -$17.27M -$11.43M -$7.65M -$7.97M -$12.76M -$12.17M -$10.78M -$5.07M -$3.43M
-725746.19% -30322.96% -1704.93% -1052.01% -228612.67%
-$27.68M -$20.5M -$14.56M -$17.21M -$11.39M -$7.52M -$7.67M -$12.49M -$11.69M -$10.31M -$4.94M -$3.41M
$16.8K $15.77K $360 $12.04K $17.99K
$1.97M $2.38M $4.05M $4.34M $877K $6000 $260 $295 $1219 $4914
-$10K -$6000 -$223K -$70K -$146K -$91K $51K $25.65K $29.3K $154 $1.6M $431 $260
-$37.64M -$34.77M -$25.5M -$30.09M -$26.96M -$20.61M -$17.83M -$17.24M -$11.4M -$8.12M -$6.37M -$12.76M -$12.17M -$10.78M -$5.08M -$3.44M
$0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
-$37.64M -$34.77M -$25.5M -$30.09M -$26.96M -$20.61M -$17.83M -$17.24M -$11.4M -$8.12M -$6.37M -$15.76M -$14.66M -$10.78M -$5.08M -$3.44M -$1.09M
-896491.64% -36518.83% -1704.94% -1054.26% -229484.53%
-$20.61M -$22.33M -$17.24M -$22.88M -$10.69M -$6.37M
USD/shares -$4.04 -$3.04 -$3.60 -$3.15 -$2.70
USD/shares -$4.04 -$3.04 -$3.60 -$3.15
shares 8.61M 8.39M 8.41M 8.44M 7.8M 753.9333 566.46K 277.18K 64.98K 196.49K 126.34K 1.6M 1.03M 830.2K 607.85K
shares 8.61M 8.39M 8.41M 8.44M 7796.6667 753.9333 566.46K 277.18K 64.98K 196.49K 126.34K 1.6M 1.03M 830.2K 607.85K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $1.48M in buybacks.

Key facts CIK 1488039 CUSIP 04962H704 13F (30d) 1 filings 1 filers Visit website Investor relations